ClinicalTrials.gg

Program

efinopegdutide

Also written as “Efinopegdutide”, “JNJ-64565111” and “JNJ-64565111 Dose Level 1”.

Its studies are mostly in Non-alcoholic Fatty Liver Disease · Obesity · Diabetes Mellitus, Type 2 · Kidney Failure, Chronic, led by 2 companies.

Furthest: phase 2, since Mar 23, 201815 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Johnson & Johnson80 open or runningphase 2since Mar 23, 2018Jun 24, 2016none ahead
Merck70 open or runningphase 2since Jun 28, 2021Jun 28, 2021none ahead
  • Named in Merck’s own pipeline as efinopegdutide (MK-6024), phase 2, as of Nov 2, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 24, 2016First study: phase 1 study in Diabetes Mellitus, Type 2New to Johnson & JohnsonJohnson & Johnson · NCT02862431 · 24 enrolled · Germany
  2. Jul 28, 2017Phase 1 study in Diabetes Mellitus, Type 2Johnson & Johnson · NCT03235219 · 39 enrolled · United States
  3. Mar 23, 2018Phase 2 study in ObesityJohnson & Johnson · NCT03486392 · 474 enrolled · United States, Belgium, Canada and more
  4. May 23, 2018Phase 1 study in Kidney Failure, ChronicJohnson & Johnson · NCT03546205 · 40 enrolled · United States
  5. Jun 22, 2018Phase 2 study in ObesityJohnson & Johnson · NCT03586830 · 196 enrolled · United States
  6. Jun 29, 2018Phase 1 study in ObesityJohnson & Johnson · NCT03586843 · 52 enrolled · United States
  7. Jul 10, 2018Phase 1 study in HealthyJohnson & Johnson · NCT03606057 · 188 enrolled · United States
  8. Aug 2, 2018Phase 1 study in HealthyJohnson & Johnson · NCT03618160 · 42 enrolled · Japan
  9. Jun 28, 2021Merck's first study: phase 2 study in Non-alcoholic Fatty Liver DiseaseNew to MerckMerck · NCT04944992 · 145 enrolled · United States, Argentina, Australia and more
  10. May 17, 2023Phase 2 study in Non-alcoholic Fatty Liver DiseaseMerck · NCT05877547 · 381 enrolled · United States, Austria, Belgium and more
  11. Sep 18, 2023Phase 1 study in Non-alcoholic Fatty Liver DiseaseMerck · NCT06052566 · 22 enrolled · United States
  12. Jun 13, 20242 phase 2 studies in Non-alcoholic Fatty Liver DiseaseMerck · NCT06465186, NCT06482112
  13. Nov 20, 2024Phase 1 study in HealthyMerck · NCT06701305 · 48 enrolled · United States
  14. Feb 18, 2025Phase 1 study in HealthyMerck · NCT06836037 · 56 enrolled · China

TargetBeta

“A synthetic peptide of oxyntomodulin conjugated to the constant region of human immunoglobulin G4 (IgG4) and dual glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist, with potential weight reducing and anti-diabetic activities and that may potentially be used for the treatment of non-alc…”NCIt, read by Claude
“Glucagon-like peptide 1 receptor agonist; Glucagon receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
survodutideBoehringer Ingelheimphase 335
retatrutideruleEli Lillyphase 333
UBT251The United Laboratories Internationalphase 312
DR10624ruleHuadong Medicinephase 36
AZD9550AstraZenecaphase 27
HRS-4729Jiangsu HengRui Medicinephase 25

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06836037Healthy · China1CompletedMerckFeb 2, 202356
NCT06701305Healthy · United States1CompletedMerckFeb 18, 202548
NCT06482112Non-alcoholic Fatty Liver Disease · United States, Puerto Rico2CompletedMerckJun 27, 2025124
NCT06465186Non-alcoholic Fatty Liver Disease · United States, Australia, Canada and more2CompletedMerckAug 3, 202685
NCT06052566Non-alcoholic Fatty Liver Disease · United States1CompletedMerckDec 5, 202422
NCT05877547Non-alcoholic Fatty Liver Disease · United States, Austria, Belgium and more2CompletedMerckDec 29, 2025381
NCT04944992Non-alcoholic Fatty Liver Disease · United States, Argentina, Australia and more2CompletedMerckOct 19, 2022145
NCT03618160Healthy · Japan1TerminatedJohnson & JohnsonJun 21, 201942
NCT03606057Healthy · United States1CompletedJohnson & JohnsonFeb 8, 2019188
NCT03586843Obesity · United States1CompletedJohnson & JohnsonMar 17, 201952
NCT03586830Obesity · United States2CompletedJohnson & JohnsonApr 5, 2019196
NCT03546205Kidney Failure, Chronic · United States1CompletedJohnson & JohnsonDec 17, 201840
NCT03486392Obesity · United States, Belgium, Canada and more2CompletedJohnson & JohnsonMar 8, 2019474
NCT03235219Diabetes Mellitus, Type 2 · United States1CompletedJohnson & JohnsonFeb 19, 201839
NCT02862431Diabetes Mellitus, Type 2 · Germany1TerminatedJohnson & JohnsonNov 29, 201624

How it is read

Names in the registry

  • “Efinopegdutide”, 6 entries
  • “JNJ-64565111”, 6 entries
  • “JNJ-64565111 Dose Level 1”, 2 entries
  • “JNJ-64565111 Dose Level 2”, 2 entries
  • “JNJ-64565111 Dose Level 3”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.